ProPhase Labs, Inc. (PRPH)

ProPhase Labs, Inc. was a diagnostics and consumer healthcare company based in Garden City, New York. It traces its origins to The Quigley Corporation, founded in 1989, which became known for the Cold-EEZE zinc lozenge. The company changed its name to ProPhase Labs in 2010.

For many years its main business was developing, manufacturing and selling over-the-counter consumer health products, including lozenges and dietary supplements. It also offered contract manufacturing services covering product development, production, warehousing and distribution. In 2017 it sold the Cold-EEZE brand to Mylan and shifted to manufacturing and new product lines.

In 2020 the company moved into diagnostic services, offering COVID-19 PCR testing through its laboratory, along with testing for respiratory pathogens. It later added genomics offerings and acquired Nebula Genomics in 2021. Diagnostic services became its largest business during the pandemic, alongside a smaller consumer products segment that included supplements such as Legendz XL and Triple Edge XL.

ProPhase common stock traded on Nasdaq under the symbol PRPH. As demand for COVID-19 testing fell after the pandemic, the diagnostic business shrank sharply, and the company faced pressure on its revenue and cash. Its share price fell, which later led to listing issues.

On December 29, 2025, ProPhase received a determination from Nasdaq staff that it no longer met the listing requirements of Listing Rule 5550(a)(2), the minimum bid price requirement for the Nasdaq Capital Market. The company did not appeal.

Trading in the common stock was suspended on January 5, 2026, so January 2, 2026 was the last day of regular Nasdaq trading, and the determination became final. Nasdaq published the delisting determination on January 23, 2026, and the stock was removed from listing at the opening of trading on February 2, 2026.

The delisting was driven by the company's share price rather than by a sale or merger, so shareholders did not receive any cash or stock consideration. After the Nasdaq suspension, the shares were no longer available for trading on the exchange, and any trading would take place in the over-the-counter market, where liquidity is typically lower and disclosure expectations differ. The company's decline reflects a broader pattern among businesses that grew quickly during the COVID-19 testing boom and then saw demand fall as the pandemic faded. Investors who followed the stock should note that a Nasdaq delisting does not by itself end a company's existence, and ProPhase's laboratory, consumer products and genomics activities were separate matters from its exchange listing. Further information on its operations would be found in its SEC filings and company announcements.